Gemcitabine treatment of experimental C6 glioma: The effects on cell cycle and apoptotic rate

Giulia Carpinelli, Barbara Bucci, Igea D'Agnano, Rossella Canese, Fabrizio Caroli, Laura Raus, Ercole Brunetti, Diana Giannarelli, Franca Podo, Carmine M. Carapella

Research output: Contribution to journalArticlepeer-review


Gemcitabine (dFdCyd) is a deoxycytidine analogue showing a broad spectrum of cytotoxic activity; additionally, at non-cytotoxic concentrations, it is a potent radiosensitiser. Its in vitro and in vivo effects were studied on C6 rat glioma. In vitro, dFdCyd induced an increase in S-phase cells at the end of treatment, with a reduction in G1 and G2 cell cycle-phase cells and relevant effects on the apoptotic rate. The in vivo effects of dFdCyd were studied on rats bearing intracranial C6 glioma. The drug was administered at a dose of 120 mg/Kg every 3 days × 4 doses. A significant effect on tumour growth was detected by longitudinal MRI analyses. Furthermore, the drug induced an inhibitory effect on tumour growth, 72 h after a 300 mg/Kg single dose. Analyses performed on tumour specimens showed relevant G1-phase accumulation and about 45% apoptotic cells. The present results justify further studies to determine the potential efficacy of dFdCyd in the treatment of malignant gliomas.

Original languageEnglish
Pages (from-to)3017-3024
Number of pages8
JournalAnticancer Research
Issue number4 B
Publication statusPublished - Jul 2006


  • Apoptosis
  • C6 glioma
  • Cell cycle
  • Gemcitabine
  • Malignant glioma
  • MRI

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Gemcitabine treatment of experimental C6 glioma: The effects on cell cycle and apoptotic rate'. Together they form a unique fingerprint.

Cite this